Tags

Type your tag names separated by a space and hit enter

Allogeneic and autologous stem cell transplantation in myelodysplastic syndromes.
Pathol Biol (Paris). 1997 Oct; 45(8):643-9.PB

Abstract

Allogeneic bone marrow transplantation is the only currently available curative treatment for myelodysplastic syndromes (MDSs) but can be used only in the minority of patients (10%) who are younger than 55 years or so and for whom an HLA-identical donor is available. Each year in Europe, about 100 patients with MDSs receive an autologous bone marrow transplant. This procedure is usually indicated as first-line treatment, except in patients without excess of blasts or complex cytogenetic abnormalities. In forms with excess of blasts, chemotherapy prior to bone marrow transplantation deserves discussion. Autologous bone marrow transplants or the more recent technique involving transplantation of autologous peripheral stem cells can be considered in patients who have achieved a complete remission under aggressive chemotherapy. This method has been followed by higher recurrence rates in patients with MDSs than in those with de novo acute myeloblastic leukemia, and randomized studies are under way to compare it with aggressive maintenance chemotherapy.

Links

clones/clone libraries

Authors+Show Affiliations

De Witte T
Department of Haematology, University Hospital St. Radboud, Nijmegen, The Netherlands.

MeSH

Bone Marrow TransplantationHematopoietic Stem Cell TransplantationHumansMyelodysplastic SyndromesTransplantation, AutologousTransplantation, Homologous

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

9569930

Citation

De Witte, T. "Allogeneic and Autologous Stem Cell Transplantation in Myelodysplastic Syndromes." Pathologie-biologie, vol. 45, no. 8, 1997, pp. 643-9.
De Witte T. Allogeneic and autologous stem cell transplantation in myelodysplastic syndromes. Pathol Biol (Paris). 1997;45(8):643-9.
De Witte, T. (1997). Allogeneic and autologous stem cell transplantation in myelodysplastic syndromes. Pathologie-biologie, 45(8), 643-9.
De Witte T. Allogeneic and Autologous Stem Cell Transplantation in Myelodysplastic Syndromes. Pathol Biol (Paris). 1997;45(8):643-9. PubMed PMID: 9569930.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Allogeneic and autologous stem cell transplantation in myelodysplastic syndromes. A1 - De Witte,T, PY - 1998/5/7/pubmed PY - 1998/5/7/medline PY - 1998/5/7/entrez SP - 643 EP - 9 JF - Pathologie-biologie JO - Pathol Biol (Paris) VL - 45 IS - 8 N2 - Allogeneic bone marrow transplantation is the only currently available curative treatment for myelodysplastic syndromes (MDSs) but can be used only in the minority of patients (10%) who are younger than 55 years or so and for whom an HLA-identical donor is available. Each year in Europe, about 100 patients with MDSs receive an autologous bone marrow transplant. This procedure is usually indicated as first-line treatment, except in patients without excess of blasts or complex cytogenetic abnormalities. In forms with excess of blasts, chemotherapy prior to bone marrow transplantation deserves discussion. Autologous bone marrow transplants or the more recent technique involving transplantation of autologous peripheral stem cells can be considered in patients who have achieved a complete remission under aggressive chemotherapy. This method has been followed by higher recurrence rates in patients with MDSs than in those with de novo acute myeloblastic leukemia, and randomized studies are under way to compare it with aggressive maintenance chemotherapy. SN - 0369-8114 UR - https://www.unboundmedicine.com/medline/citation/9569930/Allogeneic_and_autologous_stem_cell_transplantation_in_myelodysplastic_syndromes_ L2 - http://www.diseaseinfosearch.org/result/7171 DB - PRIME DP - Unbound Medicine ER -